Mumbai : Shares of Sudeep Pharma, which is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries, debuted on the exchange to close at a 30.5% premium.

The scrip listed at Rs 734 and Rs 730 per share on the BSE and NSE respectively. Immediately after the listing, the stock showed impressive upside movement and closed the day with a premium. The company’s share price closed at Rs 773.7 per share on the BSE, a 30.5% premium, and at Rs 771.9 per share on the NSE, a 30.2 % premium.

As per NSE, the total quantity traded stood at 397.5 lakh shares, on BSE the total Quantity stood at 48.9 lakh shares. Total Turnover (BSE+NSE) on Day 1 stood at Rs 3,406.9 crore.

The Market Capitalisation of the Company at today’s closing price stood at Rs 8,738 crore as per BSE and Rs 8,717.9 crore as per NSE.

The company had offered Rs 895 crore issue for subscription from November 21 to November 25. This garnered substantial interest, and the offer was subscribed nearly 93.7 times. Qualified Institutional Investors Portion and Non-institutional investor portion were subscribed 213.1 times and 116.7 times respectively. Retail Investors Portion was subscribed 15.7 times.

The company is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem. The company leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. 

It has established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. The company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons, as of June 30, 2025 (Source: F&S Report). As of the same date, one of its manufacturing Facilities have been approved by the United States Food and Drug Administration (USFDA) for the manufacture of mineral-based ingredients.